Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 33

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 33
---
PLISAV - B Advance differentiated vaccine pipeline using core technology Identify strategic opportunities to accelerate growth leveraging our fully integrated business platform Opportunistically return capital to stockholders 1 2 3 4 Delivered +203% total stockholder return 1 Achieved market share leadership in highly competitive U.S hepatitis B adult vaccine market Recognized >$950M in revenue from business development efforts during COVID - 19 x x x x .. And Has Delivered Strong Results $200M share repurchase program (~15% of market cap) 4 x Grown HEPLISAV - B revenue at ~ 65 % CAGR 2

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax is Delivering Superior Value for Stockholders © Copyright DYNAVAX 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Dynavax is Delivering Superior Value for Stockholders 45 | Following Our Successful Pivot, Dynavax is Delivering for Stockholders • Management and the Board transformed Dynavax from a struggling biotech company into a powerful commercial - stage vaccine company with an industry - leading profitable vaccine, a promising pipeline, and a strong foundation for growth • Dynavax delivered 203% total return to stockholders over the last five years while vaccine peers returned 9% and the S&P Biotechnology Select Industry Index (XBI) declined 17% over the same period (as of 17 - Apr - 2025 definitive proxy filing) • HEPLISAV - B is now the market - leading hepatitis B vaccine with $268M of revenue in 2024 and 44% U.S. market share as of year - end 2024 • Dynavax drove a successful business development strategy during the pandemic establishing a global portfolio of CpG 1018 adjuvant commercial supply agreements supporting the development of COVID - 19 vaccines, which generated >$950M in net product revenue from 2020 to 2022 • The Board and Management apply a disciplined approach to capital allocation pursuing attractive internal and